Drug Guidance for Subsidy 04/01/2022 Disease-modifying therapies for treating multiple sclerosis The Ministry of Health’s Drug Advisory Committee has recommended: Fingolimod 0.25 mg and 0.5 ... See all × 04/01/2022 Disease-modifying therapies for treating multiple sclerosis The Ministry of Health’s Drug Advisory Committee has recommended: Fingolimod 0.25 mg and 0.5 mg capsules for treating adults and children with relapsing-remitting multiple sclerosis, and Siponimod 0.25 mg and 2 mg tablets for treating adults with secondary progressive multiple sclerosis with active disease evidenced by relapses or imaging features of inflammatory activity. Subsidy status RFingolimod 0.25 mg and 0.5 mg capsules and siponimod 0.25 mg and 2 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications. NRMAF assistance does not apply to any formulations or strengths of alemtuzumab, cladribine, dimethyl fumarate, interferon beta-1a, natalizumab, ofatumumab or teriflunomide for treating adults or children with any form of multiple sclerosis.
Post Marketing Information DHCPL 14/07/2020 Lemtrada (alemtuzumab): Revised indications, additional contraindications and risk minimisation measures DHCPL 24/06/2019 Alemtuzumab (Lemtrada): Risks of immune-mediated reactions and serious cardiovascular adverse events occurring in close temporal association with Lemtrada infusions PEM 29/11/2022 A healthcare professional’s guide to using LEMTRADA® (alemtuzumab) in patients with relapsing remitting multiple sclerosis (RRMS) PMG 29/11/2022 Patient Guide: Important Information for Patients Starting Therapy with LEMTRADA® PAC 29/11/2022 LEMTRADA® Patient Alert Card
INTRAVENOUS Select a brand starting with the letter: L LEMTRADA CONCENTRATE FOR SOLUTION FOR INFUSION 12 MG/ 1.2 ML [SIN14919P]